Lilly, Zepbound and LifeMD
LifeMD® Announces Integration with LillyDirect Pharmacy Provider to Offer Patients Streamlined Access to Branded Dual GLP-1/GIP Zepbound
(Nasdaq: LFMD), a leading provider of virtual primary care services, today announced it is integrating with LillyDirect pharmacy provider, Gifthealth, to offer streamlined access of single-dose vials of Lilly’s prescription obesity treatment Zepbound ® (tirzepatide) to eligible LifeMD patients.
Craig-Hallum analyst Alex Fuhrman maintained a Buy rating on LifeMD (LFMD – Research Report) today. The company’s shares closed last Friday at ...
Telehealth firms Teladoc and LifeMD said on Thursday they had signed an agreement to offer Eli Lilly's weight-loss drug ...
We came across a bullish thesis on LifeMD, Inc. (LFMD) on Twitter by Cluseau Investments. In this article, we will summarize ...
LifeMD Inc (NASDAQ:LFMD) is set to release its Q4 2024 earnings on March 10, 2025. The consensus estimate for Q4 2024 revenue ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xtant Medical Holdings (XTNT – Research Report) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback